Browsing by Author "Albiger, Barbara"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Carbapenemase-producing Enterobacteriaceaein Europe: assessment by national experts from 38 countries, May 2015Publication . Albiger, Barbara; Glasner, Corinna; Struelens, Marc J.; Grundmann, Hajo; Monnet, Dominique L.; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working groupIn 2012, the European Centre for Disease Prevention and Control (ECDC) launched the 'European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE)' project to gain insights into the occurrence and epidemiology of carbapenemase-producing Enterobacteriaceae (CPE), to increase the awareness of the spread of CPE, and to build and enhance the laboratory capacity for diagnosis and surveillance of CPE in Europe. Data collected through a post-EuSCAPE feedback questionnaire in May 2015 documented improvement compared with 2013 in capacity and ability to detect CPE and identify the different carbapenemases genes in the 38 participating countries, thus contributing to their awareness of and knowledge about the spread of CPE. Over the last two years, the epidemiological situation of CPE worsened, in particular with the rapid spread of carbapenem-hydrolysing oxacillinase-48 (OXA-48)- and New Delhi metallo-beta-lactamase (NDM)-producing Enterobacteriaceae. In 2015, 13/38 countries reported inter-regional spread of or an endemic situation for CPE, compared with 6/38 in 2013. Only three countries replied that they had not identified one single case of CPE. The ongoing spread of CPE represents an increasing threat to patient safety in European hospitals, and a majority of countries reacted by establishing national CPE surveillances systems and issuing guidance on control measures for health professionals. However, 14 countries still lacked specific national guidelines for prevention and control of CPE in mid-2015.
- Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational studyPublication . Grundmann, Hajo; Glasner, Corinna; Albiger, Barbara; Aanensen, David M.; Tomlinson, Chris T.; Andrasević, Arjana Tambić; Cantón, Rafael; Carmeli, Yehuda; Friedrich, Alexander W.; Giske, Christian G.; Glupczynski, Youri; Gniadkowski, Marek; Livermore, David M.; Nordmann, Patrice; Poirel, Laurent; Rossolini, Gian M.; Seifert, Harald; Vatopoulos, Alkiviadis; Walsh, Timothy; Woodford, Neil; Monnet, Dominique L.; EuSCAPE Working Group; Koraqi, A..; Lacej, D.; Apfalter, P.; Hartl, R.; Glupczynski, Y.; Huang, T.D.; Strateva, T; Marteva-Proevska, Y.; Tambic, Andrasevic A.; Butic, I.; Pieridou-Bagatzouni, D.; Maikanti-Charalampous, P.; Hrabak, J.; Zemlickova, H.; Hammerum, A.; Jakobsen, L.; Ivanova, M.; Pavelkovich, A.; Jalava, J.; Österblad, M.; Dortet, L.; Vaux, S.; Kaase, M.; Gatermann, S.G.; Vatopoulos, A.; Tryfinopoulou, K.; Tóth, A.; Jánvári, L.; Boo, T.W.; McGrath, E.; Carmeli, Y.; Adler, A.; Pantosti, A.; Monaco, M.; Raka, L.; Kurti, A.; Balode, A.; Saule, M.; Miciuleviciene, J.; Mierauskaite, A.; Perrin -Weniger, M.; Reichert, P.; Nestorova, N.; Debattista, S.; Mijovic, G.; Lopicic, M.; Samuelsen, Ø.; Haldorsen, B.J.; Żabicka, D.; Literacka, E.; Caniça, M.; Manageiro, V.; Kaftandzieva, A.; Trajkovska-Dokic, E.; Damian, M.; Lixandru, B.; Jelesic, Z.; Trudic, A.; Niks, M.; Schreterova, E.; Pirs, M.; Cerar, T.; Oteo, J.; Aracil, B.; Giske, C.; Sjöström, K.; Gür, D.; Cakar, A.; Woodford, N.; Hopkins, K.; Wiuff, C.; Brown, D.J.BACKGROUND: Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it difficult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the first structured survey on the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European hospitals. METHODS: National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert laboratories, which made laboratory-substantiated information available for central analysis. FINDINGS: Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals in 36 countries submitted 2703 clinical isolates (2301 [85%] K pneumoniae and 402 (15%) E coli). 850 (37%) of 2301 K pneumoniae samples and 77 (19%) of 402 E coli samples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 11:1. 1·3 patients per 10 000 hospital admissions had positive clinical specimens. Prevalence differed greatly, with the highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high resistance to last-line antibiotics. INTERPRETATION: This initiative shows an encouraging commitment by all participants, and suggests that challenges in the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Enterobacteriaeceae can be overcome. Strengthening infection control efforts in hospitals is crucial for controlling spread through local and national health care networks.
- Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018Publication . Brolund, Alma; Lagerqvist, Nina; Byfors, Sara; Struelens, Marc J.; Monnet, Dominique L.; Albiger, Barbara; Kohlenberg, Anke; European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) capacity survey group, Vera)A survey on the epidemiological situation, surveillance and containment activities for carbapenemase-producing Enterobacteriaceae (CPE) was conducted in European countries in 2018. All 37 participating countries reported CPE cases. Since 2015, the epidemiological stage of CPE expansion has increased in 11 countries. Reference laboratory capability, dedicated surveillance and a specific national containment plan are in existence in 33, 27 and 14 countries, respectively. Enhanced control efforts are needed for CPE containment in Europe.